Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma
Antoine Hollebecque(Institut Gustave Roussy), Monica Mita(Novartis (Switzerland)), Marc Webster, Lisa Nabell(University of Alabama at Birmingham), Sarah Gordon(Virginia Commonwealth University), Geoffrey I. Shapiro(Brigham and Women's Hospital), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Sarah P. Blagden(Churchill Hospital), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Benoît You(Communauté urbaine de Lyon), Sarit Assouline(Jewish General Hospital), Dima El‐Sharkawi(Royal Marsden Hospital), Martin J.S. Dyer(University of Leicester), John Lister(Allegheny Health Network), Danna Chan(Astex Pharmaceuticals), Yijun Sun(Astex Pharmaceuticals), Roberta Ferraldeschi(Royal Marsden NHS Foundation Trust), Francine Foss(Yale Cancer Center), Anca Prica(Princess Margaret Cancer Centre)
Cited by 2
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k